Sofosbuvir/velpatasvir/voxilaprevir (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sofosbuvir/velpatasvir/voxilaprevir" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

68^th place

117^th place

1,712^th place

1,063^rd place

2^nd place

2^nd place

1web.archive.org

1^st place

1^st place

447^th place

338^th place

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

"Liver disease". Health Canada. 9 May 2018. Retrieved 13 April 2024.

doi.org (Global: 2^nd place; English: 2^nd place)

Childs-Kean LM, Brumwell NA, Lodl EF (2019). "Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C". Infection and Drug Resistance. 12: 2259–2268. doi:10.2147/IDR.S171338. PMC 6662169. PMID 31413603.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Vosevi EPAR". European Medicines Agency (EMA). 22 September 2017. Retrieved 24 September 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

"Vosevi PI". Union Register of medicinal products. 28 July 2017. Retrieved 29 June 2024.

fda.gov (Global: 447^th place; English: 338^th place)

"FDA approves Vosevi for Hepatitis C". U.S. Food and Drug Administration (FDA) (Press release). 18 July 2017. Archived from the original on 23 July 2017. Retrieved 27 July 2017. This article incorporates text from this source, which is in the public domain.

nih.gov (Global: 4^th place; English: 4^th place)

dailymed.nlm.nih.gov

"Vosevi- sofosbuvir, velpatasvir, and voxilaprevir tablet, film coated". DailyMed. 14 March 2024. Retrieved 29 June 2024.

ncbi.nlm.nih.gov

Childs-Kean LM, Brumwell NA, Lodl EF (2019). "Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C". Infection and Drug Resistance. 12: 2259–2268. doi:10.2147/IDR.S171338. PMC 6662169. PMID 31413603.

pubmed.ncbi.nlm.nih.gov

Childs-Kean LM, Brumwell NA, Lodl EF (2019). "Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C". Infection and Drug Resistance. 12: 2259–2268. doi:10.2147/IDR.S171338. PMC 6662169. PMID 31413603.

web.archive.org (Global: 1^st place; English: 1^st place)

"FDA approves Vosevi for Hepatitis C". U.S. Food and Drug Administration (FDA) (Press release). 18 July 2017. Archived from the original on 23 July 2017. Retrieved 27 July 2017. This article incorporates text from this source, which is in the public domain.